Find Funding Opportunities

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) is to issue a Request for Applications (RFA) to investigate CNS changes that occur with chronic pain, and how these changes parallel those that occur with drug addiction. Of interest will be how chronic pain changes the CNS, how analgesics of various classes impact pain-induced CNS changes, and how analgesics in the absence of pain (some of which have abuse potential) produce CNS changes. The temporal course of these changes will also be of interest.A focus of this research will be comparing and contrasting these CNS changes in an effort to identify shared and unique mechanisms involved in pain, analgesia and drug abuse, as well as environmental and genetic factors that influence these changes. -Mechanism of Support. This FOA will utilize the R03 grant mechanism and runs in parallel with two FOAs of identical scientific scope, RFA-DA-09-017 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-017) and RFA-DA-09-018 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-018), that solicit applications under the R01 and R21 mechanisms, respectively. -Funds Available and Anticipated Number of Awards. The NIDA has set aside $2,000,000 to fund an anticipated 6-10 grant applications and the NINDS has set aside $375,000 to fund an anticipated two grants for this FOA and its companion R01 and R21.

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) is to issue a Request for Applications (RFA) to investigate CNS changes that occur with chronic pain, and how these changes parallel those that occur with drug addiction. Of interest will be how chronic pain changes the CNS, how analgesics of various classes impact pain-induced CNS changes, and how analgesics in the absence of pain (some of which have abuse potential) produce CNS changes. The temporal course of these changes will also be of interest.A focus of this research will be comparing and contrasting these CNS changes in an effort to identify shared and unique mechanisms involved in pain, analgesia and drug abuse, as well as environmental and genetic factors that influence these changes. -Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with two FOAs of identical scientific scope, RFA-DA-09-018 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-018) and RFA-DA-09-019 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-019), that solicit applications under the R21 and R03 mechanisms, respectively.

-Purpose. The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) is to issue a Request for Applications (RFA) to investigate CNS changes that occur with chronic pain and how these changes parallel those that occur with drug addiction. Of interest will be how chronic pain changes the CNS, how analgesics of various classes impact pain-induced CNS changes, and how analgesics in the absence of pain (some of which have abuse potential) produce CNS changes. The temporal course of these changes will also be of interest.A focus of this research will be comparing and contrasting these CNS changes in an effort to identify shared and unique mechanisms involved in pain, analgesia and drug abuse, as well as environmental and genetic factors that influence these changes. -Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with two FOAs of identical scientific scope, RFA-DA-09-017 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-017) and RFA-DA-09-019 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-019), that solicit applications under the R01 and R03 mechanisms, respectively. -Funds Available and Anticipated Number of Awards. The NIDA has set aside $2,000,000 to fund an anticipated 6-10 grant applications and the NINDS has set aside $375,000 to fund an anticipated two grants for this FOA and its companion R01 and R03.

-Purpose. This funding opportunity announcement (FOA), administered by the National Cancer Institute, is a part of the Genes, Environment, and Health Initiative (GEI, http://www.gei.nih.gov/) sponsored by the National Institutes of Health (NIH). The purpose of this FOA is to provide support for replication and fine-mapping studies of genetic regions that are putatively associated with common complex traits, primarily those identified by genome-wide association studies (GWAS). The proposed projects should aim to enhance the identification of causal variants influencing complex diseases. Any phenotype may be appropriate for these projects (i.e., studies need not be oriented on cancer or cancer-related phenotypes). This FOA will not support recruitment of human subjects, collection of human specimens, collection of medical or phenotype data, studies using animal models, or discovery genome-wide association efforts. -Mechanism of Support. This FOA will utilize the NIH research project (R01) grant mechanism. -Funds Available and Anticipated Number of Awards. The NCI has set aside $2 million in Fiscal Year 2009 for 4-6 awards under this FOA.

-Purpose. This FOA invites R01 applications for mechanistic studies in clinical trials of: (1) immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft rejection in solid organ, cell, and tissue transplantation; graft versus host disease in hematopoietic stem cell transplantation; and chronic inflammatory, autoimmune, and immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents of bioterrorism and emerging/re-emerging infectious diseases. This FOA is a renewal with modifications of RFA AI-05-028 (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-05-028.html). In order to review and confer awards to grant applications received in response to this FOA in a timely fashion, without delay of the parent clinical trial, applications submitted in response to the FOA will be subject to an accelerated review/award process. Highly meritorious applications selected for funding under this FOA may receive their awards as early as thirteen weeks after the application receipt date. Holidays and other circumstances may alter this schedule slightly. -Mechanism of Support. This FOA will utilize the NIH Research Project grant (R01) mechanism.

-Purpose. This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME/CFS) in diverse groups and across the lifespan. Innovative applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, and the common mechanisms influencing the multiple body systems that are affected in CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with CFS. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-08-247, that encourages applications under the NIH Exploratory/Developmental (R21) grant mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -Budget and Project Period. Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

-Purpose. This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME/CFS) in diverse groups and across the lifespan. Innovative applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, and the common mechanisms influencing the multiple body systems that are affected in CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with CFS. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanismand runs in parallel with a FOA of identical scientific scope, PA-08-246 that encourages applications under the,(R01) mechanism -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

-Purpose. This FOA solicits Research Project Grant (R01) applications from institutions/organizations proposing exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or biobehavioral research that is germane to the mission of one or more of the participating NIH Institutes. This FOA is for support of new projects, not continuation of projects that have already been initiated. It does not support pilot projects, i.e., projects of limited scope that are designed primarily to generate data that will enable the PI to seek other funding opportunities. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. NIGMS ($6 million, 18-22 awards), NCI ($750,000, 2-3 awards), NIA ($1 million, 2-3 awards), NIAAA ($600,000, 2 awards), NIDCR ($750,000, 2-3 awards), NIDA ($1 million, 3-4 awards), NIMH ($3 million, 8-12 awards), NINDS ($2 million, 6 awards), and NLM ($985,000. 3 awards) are participating in this initiative. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. The goal of this funding opportunity announcement (FOA) is to support pre-clinical development and testing of new therapies for neurological disorders.The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing.This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target.The program supports pre-clinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as high throughput screening.The program also excludes clinical research, basic research, and studies of disease mechanism.This is a milestone-driven cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress. -Mechanism of Support. This FOA will utilize the U01 Research Project Cooperative Agreements grant mechanism.

-Purpose. The goal of this funding opportunity announcement (FOA) is to implement a program of cooperative agreements that will support milestone-driven resource-related projects focused on providing products and services that are required for the pre-clinical testing of new therapeutics, and that are specific to neurology. -Mechanism of Support. This FOA will utilize the U24 Resource-Related Research Projects Cooperative Agreements grant mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.